Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor in Multiple Myeloma

A new staging system for multiple myeloma (MM) has utilized serum concentrations of beta 2-microglobulin (Sβ2M) and albumin as important prognostic factors for survival. Since Sβ2M is an indicator of glomerular filtration rate, we compared the prognostic values of Sβ2M and 24-hr urinary creatinine clearance (Ccr) in patients with MM. We retrospectively reviewed the records of 170 MM patients from January 1996 to November 2003 whose 24-hr urinary Ccr was available at the time of diagnosis. We found that pretreatment Sβ2M was inversely related to Ccr (Spearman’s correlation coefficient=-0.787). In univariate analysis, the hazard ratio (HR) of death was 1.043 (p<0.001) for Sβ2M and 0.985 (p<0.001) for Ccr. Multivariate analysis showed that Sβ2M (HR 1.030, p=0.010) and Ccr (HR 0.993, p=0.059) were significant prognostic factors in patients’ survival. In conclusion, 24-hr urinary Ccr may be utilized for staging of patients with MM.

Key Words: Multiple Myeloma; beta 2-Microglobulin; Glomerular Filtration Rate

INTRODUCTION

Until recently, the Durie Salmon (DS) staging system was primarily used in patients with multiple myeloma (MM) (1). This staging system was designed according to cell mass, utilizing hemoglobin, serum calcium, lytic bone lesions, and M component production rates as measurements, with each stage divided into A and B subgroups according to renal function.

More recently, the Southwest Oncology Group (SWOG) introduced a new staging system with beta 2-microglobulin (Sβ2M) and albumin as prognostic factors (2). The SWOG staging system has been regarded as an easy, as well as good indicator of event-free survival, first-year mortality, and long-term survival. However, the SWOG system still requires more time and practice until it becomes the standard method.

Sβ2M, which is thought to reflect known tumor cell burden, has been regarded as the most important prognostic factor in MM. Although Sβ2M concentration is influenced by kidney function, multivariate analysis showed that it remains an independent prognostic factor after correction for serum creatinine concentration (3-7).

However, in patients with mild to moderate renal insufficiency, Sβ2M may be a better indicator of glomerular filtration rate (GFR) than serum creatinine (8, 9). We therefore compared Sβ2M with 24 urinary Ccr as prognostic factors in MM patients, and determined the significance of 24 hr urinary creatinine clearance (Ccr) in the staging of patients with MM.

MATERIALS AND METHODS

We retrospectively reviewed the records of all 268 symptomatic MM patients admitted and newly diagnosed at Asan Medical Center, Seoul, Korea, from 1 January 1996 to 30 November 2003. The 24-hr urinary Ccr was available at the time of diagnosis for 170 of these symptomatic MM patients, and these 170 patients were enrolled into the study. Survival time was followed until 30 April 2005.

All the patients had symptomatic MM in accordance with the diagnostic criteria of the International Myeloma Working Group (2003) (11). These criteria are defined as: 1) M-protein in serum and/or urine; 2) bone marrow (clonal) plasma cells or plasmacytomas; 3) related organ or tissue impairment (end organ damage, including bone lesions); and 4) no minimal level of clonal bone marrow plasma cells.

Patients with nonsecretory myeloma, smoldering multiple myeloma, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes), plasma cell leukemia, light chain deposit disease, MGUS (monoclonal gammopathy of undermined significance), extramedullary plasmacytoma, a combination of other malignancies, severe trauma were excluded.
Parameters

We investigated age, sex, heavy chain types, light chain types, Durie-Salmon stage, $S_\beta: M$, hemoglobin, serum calcium, serum albumin, serum creatinine, and 24 hr urine creatinine clearance before chemotherapy. $S_\beta: M$ was measured by a radioimmunoassay with $^{125}$I- labeled beta 2-microglobulin.

Treatment

Whereas patients received various treatments, they could be divided into 3 groups; those who received conservative treatment (no treatment or dexamethasone [20 mg/m$^2$ orally] only), those who received conventional chemotherapy (e.g., VAD, MP, high dose cytoxan plus prednisolone, and thalidomide plus dexamethasone regimens), and those who received autologous stem cell transplantation.

The MP regimen consisted of melphalan (8 mg/m$^2$) and prednisolone (60 mg/m$^2$) for 4 days; the VAD regimen consisted of vincristine (0.4 mg), doxorubicin (9 mg/m$^2$) for 4 days, and dexamethasone (40 mg) for 12 days. The high dose cytoxan plus prednisolone regimen consisted of cytoxan (400 mg/m$^2$) for 1 day and prednisolone (40 mg/m$^2$) for 7 days and was a variant of the VBMCP (vincristine, BCNU, melphalan, cytoxan, prednisolone) regimen. The thalidomide plus dexamethasone regimen consisted of 200 mg thalidomide orally per day plus 5 to 10 mg dexamethasone intravenously 4 times per day.

Survival time

Medical records were used to collect data. Interviews with patients’ families by telephone and data from the hospital network connected to the Korean National Statistical Office were also utilized to determine the patient survival times.

Staging system

Patients were divided depending on DS stage, which was assigned by physicians who first examined them (1). Then, they were sorted by SWOG staging system according to $S_\beta: M$ and albumin concentrations (2).

SWOG stage 1 was defined as $S_\beta: M < 2.5$ mg/L; stage 2 as $2.5$ mg/L $\leq S_\beta: M < 5.5$ mg/L; stage 3, $S_\beta: M \geq 5.5$ mg/L and serum albumin $\geq 3.0$ g/dL; and stage 4, $S_\beta: M \geq 5.5$ mg/L and albumin $< 3.0$ g/dL.

During the course of this study, we formulated a new experimental staging system based on 24 hr urinary Ccr and serum albumin. In this system, stage 1 defined as Ccr $\geq 90$ mL/min; stage 2 as 90 mL/min $>\text{Ccr} \geq 30$ mL/min; stage 3 as Ccr $< 30$ mL/min and albumin $\geq 3.0$ g/dL; stage 4 as Ccr $< 30$ mL/min and albumin $< 3.0$ g/dL.

Statistical analysis

SPSS (version 11.0) was used to determine the means and standard deviations and medians of patient characteristics of patients and laboratory findings. One-way ANOVA and Student’s t test were used to compare mean Ccr according to heavy or light chain types. An interactive graph of Ccr and $S_\beta: M$ was drawn using a scatter plot and a logarithmic estimated curve.

The Kaplan-Meier method was utilized for survival analysis with log rank test; statistical significance was defined as $p$ value less than 0.05.

The Cox proportional hazard model was employed for univariate analysis and multivariate analyses to confirm the significance of risk factors of death. In multivariate analysis, we used eliminated variables stepwise (backward) by a significance of less than 10%.

RESULTS

Study population

From 1 January 1996, through 30 November 2003, 289 patients with plasma cell disorders were admitted to our Center. Among them, there were 268 symptomatic MM patients. We excluded 14 patients with other monoclonal gammapathies and 7 patients with combining other malignancy or severe trauma. Gammapathies other than symptomatic multiple myeloma were 3 MUGS, 2 plasma cell leukemia, 2 smoldering MM, 2 nonsecretory MM, 1 extramedullary plasmacytoma, 1 multiple solitary plasmacytoma, and 3 POEMS. As to 170 patients, 24-hr urinary creatinine clearance was available at the time of diagnosis. Baseline characteristics and laboratory findings at the time of diagnosis are shown in Table 1.

Table 1 shows the mean Ccr of each type. The mean Ccr in patients with free light chain was lower than those of the heavy and light chain type groups. Mean Ccr of patients with free light chain was 36.2 mL/min, whereas those of patients with IgG type and IgA were 54.9 mL/min and 62.2 mL/min ($p=0.005$), respectively. However, mean $S_\beta: M$ of patients

| Mean $\pm$ SD or Median (Range) | (n=170) |
|-------------------------------|--------|
| Age (yr)                      | 60.0 (29-90) |
| Sex (male:female)             | 107:63 |
| Hemoglobin (g/dL)             | 9.1 $\pm$ 2.3 |
| Serum calcium (mg/dL)         | 9.5 $\pm$ 1.8 |
| Serum creatinine (mg/dL)      | 1.5 (0.5-17.6) |
| Serum beta 2-microglobulin ($\mu g/mL$) | 5.5 (1.2-48.4) |
| Serum albumin (g/dL)          | 3.2 $\pm$ 0.8 |
| Creatinine clearance (mL/min) | 47.8 (0.2-140.7) |
according to heavy chain types was not significantly different ($p=0.156$).

Of the 170 patients, 28 patients were managed conservatively, 92 patients were treated with conventional chemotherapy, and 50 patients received high-dose chemotherapy with autologous stem cell transplantations. The first-line chemotherapy regimens consisted of VAD in 94 patients, MP in 41, cytoxan plus prednisolone in 4, thalidomide plus dexamethasone in 1. The chemotherapy regimen was unidentified in 2 patients.

We could definitively identify cause of death only if patients died in hospital, although we attempted to interview by telephone family members of patients who died outside of hospital. Of the 51 patients who died in hospital, although we attempted to interview by telephone family members of patients who died outside of hospital, We could definitively identify cause of death only if patients died in hospital, although we attempted to interview by telephone family members of patients who died outside of hospital.

Table 2. Types of heavy chains and light chains

| Heavy chain type | Ccr (mean±SD) (mL/min) | Sβ2-M (mean±SD) (µg/mL) |
|------------------|------------------------|-------------------------|
| IgG              | 54.9±37.9              | 9.9±11.4                |
| IgA              | 62.2±35.7              | 8.1±9.2                 |
| Free light chain | 36.2±31.0*             | 13.3±11.4               |
| IgD              | 50.3±36.7              | 10.5±8.2                |
| IgM              | 1 (102.6)              | (2.6)                   |
| Kappa            | 51.9±35.7              | 10.4±11.1               |

| Light chain type | Ccr (mean±SD) (mL/min) | Sβ2-M (mean±SD) (µg/mL) |
|------------------|------------------------|-------------------------|
| Lambda           | 50.1±37.8              | 10.5±10.6               |
| Kappa            | 51.9±35.7              | 10.4±11.1               |

* $p<0.05$ between patients with IgG type and free light chain type, or between IgA type and free light chain type. One with only IgG heavy chain type was excluded.

Multivariate analysis of prognostic factors using the Cox proportional hazard model showed that serum $Sβ2-M$, creatinine clearance, and treatment modalities were significant prognostic factors in continuous method (Table 6). Ccr was of borderline significance and was not eliminated by backward stepwise calculation if $p=0.10$. Using the dichotomous method, however, the result was somewhat different. If the Ccr cut-off value was 30 mL/min and that of $Sβ2-M$ was 5.5 mg/L, Ccr and treatment were significant, but $Sβ2-M$ concentration was not. This discrepancy was due to the close relationship of $Sβ2-M$ and Ccr, making it difficult to determine a standard cutoff value using the dichotomous method.

Table 3. Hazard ratio in univariate analysis

| Continuous HR, $p$ value | Dichotomous Cutoff value, HR, $p$ value |
|--------------------------|-----------------------------------------|
| Age (yr)                 | 1.038, $p<0.001$                        | 1.972, $p<0.001$ |
| Sex (male:female)        | Male $1.075$, female $0.711$            | NS               |
| Hemoglobin (g/dL)        | 0.954, $p=0.259$ NS                     | 0.850, $p=0.386$ |
| Serum calcium (mg/dL)    | 1.106, $p=0.026$                        | 1.524, $p=0.045$ |
| Serum creatinine (mg/dL) | 1.101, $p<0.001$ ≥1.5                   | 2.077, $p<0.001$ |
| Serum beta 2-microglobulin (µg/mL) | 1.043, $p<0.001$ ≥5.5 | 2.097, $p<0.001$ |
| Serum albumin (g/dL)     | 0.916, $p=0.469$ NS                    | 0.987, $p=0.944$ |
| Creatinine clearance (mL/min) | 0.985, $p<0.001$ ≥30 | 0.361, $p<0.001$ |
| Heavy chain type*        | Only light Heavy and light chain        | 1.525, $p=0.032$ |
| Light chain type         | Kappa $0.753$, Lambda $0.135$           | NS               |

* $p<0.05$ between patients with IgG type and free light chain type, or between IgA type and free light chain type. One with only IgG heavy chain type was excluded.

Table 4. Hazard ratio in univariate analysis if Ccr ≥30 mL/min

| Continuous HR, $p$ value | Dichotomous Cutoff value, HR, $p$ value |
|--------------------------|-----------------------------------------|
| $Sβ2-M$ (µg/mL)          | ≥5.5, $p=0.982$                           | 1.114, $p=0.736$ |
| Ccr (mL/min)             | 0.987, $p=0.015$ ≥90                     | 0.499, $p=0.034$ |

$Sβ2-M$, Serum beta 2-microglobulin; Ccr, Creatinine clearance; HR, hazard risk of death.
Correlation of beta 2-microglobulin and creatinine clearance

When we drew a scatter plot of S2M and Ccr prior to the start of chemotherapy (Fig. 1), we found that pretreatment S2M was inversely related to Ccr (Spearman’s correlation efficient -0.787, p<0.001).

Stage

Fig. 2 shows survival curves relative to DS stage and SWOG stage. Because we enrolled only patients whose DS stage was recorded by doctors at the time of diagnosis, the total number according to DS stage was 147 (95 dead, 52 alive). Because S2M was not checked in 3 patients in the study group, the total number according to SWOG stage was 167 (112 dead, 55 alive).

Median overall survival times according to DS stage were 919 days for stage 1 (n=11), 1011 days for stage 2 (n=17), 925 days for stage 3A (n=66), and 380 days for stage 3B (n=53).

Median survival times according to SWOG stage were 1475 days for stage 1 (n=18), 917 days for stage 2 (n=65), 453 days for stage 3 (n=57), and 152 days for stage 4 (n=27) (log rank test <0.0001).

Possible staging system

Univariate analysis showed that, as Ccr increased, patient
survival time increased. Furthermore Sβ:M was closely related with Ccr. We therefore formulated a new staging system based on Ccr instead of Sβ:M, plus serum albumin (Fig. 3). According to this system, stage 1 is Ccr ≥ 90 mL/min; stage 2 is 90 mL/min > Ccr ≥ 30 mL/min; stage 3 is Ccr < 30 mL/min and albumin ≥ 3.0 g/dL; stage 4, Ccr < 30 mL/min and albumin < 3.0 g/dL.

Applying this system, we found that 30 patients (12 dead, 18 alive) were stage 1, 74 (44 dead, 30 alive) were stage 2, 46 (42 dead, 4 alive) were stage 3, and 20 (17 dead, 3 alive) were stage 4.

According to this staging system, the median survival times were 1,475 days for stage 1, 889 days for stage 2, 339 days for stage 3, and 95 days for stage 4 (log rank test < 0.0001).

**DISCUSSION**

In MM, the importance of Sβ:M has led to the introduction of the SWOG staging system. In an attempt to determine the relationship between Sβ:M and kidney function and to choose a more significant prognostic factor, we were unable to find any study that included both 24 hr urinary Ccr and Sβ:M as prognostic factors. Thus, to our knowledge, this study is the first to include both of these as prognostic factors.

We found that in MM, Sβ:M and Ccr were more closely related than we expected. Multivariate analysis showed that Sβ:M, Ccr, and treatment modalities were independent prognostic factors. Thus, the results of this study suggest that Ccr is a new, powerful prognostic factor in the patients with MM. Moreover, this finding indicates that Ccr can be incorporated into a discrete new staging system for MM.

It was interesting that Sβ:M was not significant in patients whose Ccr was greater than 30 mL/min. That is, the incremental addition of Sβ:M concentration was not a significant prognostic factor if kidney function was relatively good. Thus, the effect of Sβ:M on patient survival might be mainly due to declining kidney function.

Our new staging system used Ccr instead of Sβ:M. The latter is not likely to be a specific tumor marker in MM. This finding indicates that patient survival is related to the decreased excretion of Sβ:M rather than to its overproduction. There is evidence that Sβ:M reflects glomerular filtration rate in many situations, although it also reflects tumor cell mass (9-11). Although our Kaplan-Meier curves of stages relative to Ccr and serum albumin concentrations were discrete, they were unable to show that Ccr was a more significant prognostic factor than Sβ:M. These two factors, plus serum creatinine, are related, and other conflicting factors affect survival, thus making interpretation difficult. Differences in mean Ccr between patients with both heavy and light chains and those with only free light chains may be related to different survival times. Although the SWOG staging system has been regarded as easier and likely to supersede the DS staging system, it is cautious to determine the superiority between the two staging systems. Serum albumin was not a significant prognostic in univariate analysis, but, in the SWOG staging system, it was important in sorting patients with advanced stage MM.

Our study had several limitations. First, we may have included patients who died accidentally, since the causes of death of patients who died outside the hospital could not be determined. Second, this retrospective study did not include important parameters such as performance status, C reactive protein, chromosome 13 abnormality, and plasma cell labeling index (12, 13).

In conclusion, we found that in patients with MM, Sβ:M was an independent significant prognostic factor in multivariate analysis that included Ccr. Although closely related to Sβ:M, Ccr was also a significant prognostic factor that could replace Sβ:M in staging systems of MM. Mean Ccr differed among heavy chain types, and these differences were likely related to different survival times.

**REFERENCES**

1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-54.
2. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ; Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441-50.
3. Cuzick J, Cooper EH, MacLennan IC. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatisis. Br J Cancer 1985; 52: 1-6.
4. Alexanian R, Barlogie B, Fritsche H. Beta 2 microglobulin in multi-
ple myeloma. Am J Hematol 1985; 20: 345-51.

5. Scarffe JH, Anderson H, Palmer MK, Crowther D. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma. Eur J Cancer Clin Oncol 1983; 19: 1361-4.

6. Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment; a prospective study of 160 patients. Blood 1984; 63: 468-76.

7. Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan IC. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. Br J Haematol 1990; 75: 506-10.

8. Donadio C, Lucchesi A, Ardini M, Giordani R. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal 2001; 24: 835-42.

9. Jovanovic D, Krstivojevic P, Obradovic I, Durdevic V, Dukanovic L. Serum cystatin C and beta2-microglobulin as markers of glomerular filtration rate. Ren Fail 2003; 25: 123-33.

10. Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G. Reappraisal of serum beta2-microglobulin as marker of GFR. Ren Fail 2001; 23: 419-29.

11. International Myeloma Working Group. Criteria for the classification of monoclonal gammapathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57.

12. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY; Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-71.

13. Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-7.